Peptide
PT-141 (Bremelanotide, Vyleesi)
FDA-approved melanocortin-4 receptor agonist for acquired generalized HSDD in premenopausal women. Off-label male use rests on abandoned-program data.
Summary Does bremelanotide improve sexual desire or erectile function? Show / hide ↓
Bremelanotide, also called PT-141, is a prescription drug that activates a brain receptor involved in sexual desire. It is approved for acquired, ongoing low sexual desire in premenopausal women, a condition called HSDD. In two large studies of 1,267 women, about 37% reported meaningful improvement in desire, compared with 28% taking a placebo, an inactive treatment. Older research in men found improved erections in 54.5% at a 1.75 mg dose, but that development program was abandoned. Nausea affected about 40% of users, and the drug can briefly raise blood pressure and cause skin darkening; it is injected 45 minutes before sex, with no more than one dose daily or eight doses monthly.
What this means for you: Bremelanotide has moderate evidence for a small improvement in sexual desire in some premenopausal women. Evidence for erectile problems in men is older and weaker, while side effects and cardiovascular warnings limit its appeal.
moderate evidencePT-141, now marketed as bremelanotide (brand name Vyleesi), is a melanocortin-4 receptor agonist. It was FDA-approved in June 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, based on the two RECONNECT phase 3 RCTs totaling approximately 1,267 women.
The efficacy in HSDD is real but modest. In the RECONNECT trials, approximately 37% of bremelanotide-treated patients reported a clinically meaningful improvement in desire versus approximately 28% on placebo, a difference of about 9 percentage points.
Off-label use in male erectile dysfunction rests on data from an abandoned development program. Approximately 54.5% of men reported improved erectile function at 1.75 mg subcutaneous dose in the historical program, but the program was discontinued in favor of the HSDD indication.
Documented constraints include transient blood-pressure rises, nausea (approximately 40% incidence), and hyperpigmentation. The FDA label warns about cardiovascular risk in patients with uncontrolled hypertension or known cardiovascular disease.
Bremelanotide is administered as a subcutaneous autoinjector 45 minutes before anticipated sexual activity, with no more than one dose per day and no more than eight doses per month. It is a prescription drug, not a research chemical.
The 'PT-141' designation persists in the peptide community where the drug is sometimes sold by research chemical vendors, bypassing the prescription-only status. This carries the same purity and contamination risks as other gray-market peptide products.
Further reading
Curated external sources for a deeper dive. External links open in a new tab.